2011年2月

技術情報

Blood or Plasma? Which Should You Assay for Drug Concentration?

Explore blood vs. plasma drug concentration assays. Learn their differences, relationships, and impact on accurate…

Nathan Teuscher2011年2月19日

Blog Knowledge Base

Why Should You Evaluate Dose Proportionality?

Dose proportionality is a common phrase used pharmacokinetics. Early in the pre-clinical development process, we…

Certara2011年2月17日

技術情報

What is the Difference Between PK and TK?

Explore the key differences between pharmacokinetics (PK) and toxicokinetics (TK), their roles in drug development,…

Nathan Teuscher2011年2月15日

技術情報

Why are PK Parameters Lognormally Distributed?

The statistical analysis of pharmacokinetic parameters is often overlooked and not always well understood. The…

Nathan Teuscher2011年2月10日

技術情報

What are Direct and Indirect Pharmacodynamic Models?

When constructing pharmacodynamic (PD) models, you will often encounter the adjectives “direct” and “indirect” describing…

Nathan Teuscher2011年2月8日

技術情報

What is Modeling and Simulation?

I am currently attending a short conference on modeling and simulation in pediatric clinical pharmacology,…

Nathan Teuscher2011年2月1日

Publication

Physiologically-based Pharmacokinetic Model for Topotecan in Mice

Topotecan is a chemotherapeutic agent of choice for the second-line treatment of recurrent ovarian cancer.…

Danielle Pillsbury2011年2月1日

Publication

Excretion of the Principal Urinary Metabolites of Phenytoin and Absolute Oral Bioavailability Determined by Use of a Stable Isotope in Patients with Epilepsy

The anticonvulsant properties of phenytoin (PHT) were discovered in 1938. Since then, it has been…

Danielle Pillsbury2011年2月1日

Publication

Poor Correlation between Urinary Excretion of the Principal Urinary Metabolites of Phenytoin and Absolute Oral Bioavailability Determined by a Stable Isotope Method in Epilepsy Patients

The anticonvulsant properties of phenytoin (PHT) were discovered in 1938. Since then, it has been…

Danielle Pillsbury2011年2月1日

Publication

Physiologically-based Pharmacokinetics in Drug Development and Regulatory Science

The application of physiologically-based pharmacokinetic (PBPK) modeling is coming of age in drug development and…

Danielle Pillsbury2011年2月1日

2011年2月

Blood or Plasma? Which Should You Assay for Drug Concentration?

Why Should You Evaluate Dose Proportionality?

What is the Difference Between PK and TK?

Why are PK Parameters Lognormally Distributed?

What are Direct and Indirect Pharmacodynamic Models?

What is Modeling and Simulation?

Physiologically-based Pharmacokinetic Model for Topotecan in Mice

Excretion of the Principal Urinary Metabolites of Phenytoin and Absolute Oral Bioavailability Determined by Use of a Stable Isotope in Patients with Epilepsy

Poor Correlation between Urinary Excretion of the Principal Urinary Metabolites of Phenytoin and Absolute Oral Bioavailability Determined by a Stable Isotope Method in Epilepsy Patients

Physiologically-based Pharmacokinetics in Drug Development and Regulatory Science

メルマガ登録

クイックアクセス

ソリューション

お問合せ